

October 4, 2018

Press Release

Nobelpharma Co., Ltd.

Launching Sales of Jemina® Tablets, a Treatment for Dysmenorrhea

Nobelpharma Co., Ltd. (Head Office: Chuo-ku, Tokyo; President and CEO: Jin Shiomura) is announcing that the Company has launched sales of a new drug product with efficacy for dysmenorrhea, Jemina® Tablets (levonorgestrel – ethinylestradiol compound formulation).

This drug is the first monophasic low-dose estrogen/progestin formulation (follicular hormone ethinylestradiol 0.02mg and progesterone levonorgestrel 0.09mg) treatment for dysmenorrhea in Japan to include levonorgestrel. There are 2 dosage methods to choose from, a cycle of 28 days with the drug administered for 21 days continuously and 7 days without dosage, and a cycle of 84 days with the drug administered for 77 days continuously and 7 days without dosage.

Nobelpharma has a business tie-up with ASKA Pharmaceutical Co., Ltd. (Head Office: Minato-ku, Tokyo; President: Takashi Yamaguchi), a specialty pharmaceutical company in the field of obstetrics and gynecology, and will work with them to promote sales of this drug to patients and to medical specialists to respond to treatment needs effectively.

【Contact for more information】

Nobelpharma Co., Ltd.

Kozo Hayase, Executive Director, Head of Administrative Affairs & Corporate Planning

Tel: 03-5651-1160

About Nobelpharma

Nobelpharma has been contributing to the provision of necessary treatments for overlooked diseases through development of medicines since 2003. Our development priority is on medicines and medical devices for unmet needs that are strongly desired by patients associations and medical associations. Currently, we have obtained marketing approval for 14 products, mostly focused on medicines and medical devices for unmet needs, and of those 10 products have received the orphan drug or device designation.